Valuation: CureVac

Market Cap 867M 989M 803M 739M 1.39B 95.25B 1.41B 9.59B 3.75B 46.68B 3.71B 3.63B 161B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 424M 484M 393M 362M 682M 46.6B 690M 4.69B 1.84B 22.84B 1.82B 1.78B 78.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer 61 01/07/2021
Director TitleAgeSince
Chairman 75 01/08/2015
Director/Board Member 58 01/08/2015
Director/Board Member 69 22/06/2022

Financials

2026 *2027 *
Net sales - -
Net income -132M -151M -123M -113M -213M -14.55B -216M -1.46B -573M -7.13B -567M -555M -24.62B -
Net Debt - -
Logo CureVac
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB